Abstract INTRODUCTION AND OBJECTIVES Risk stratification is important in the management of metabolic dysfunction-associated steatotic liver disease (MASLD) to prioritize monitoring and treatment resources. We evaluated whether non-invasive tests (NITs) can predict major adverse liver outcomes (MALOs) and diagnose advanced fibrosis in patients with MASLD. PATIENTS AND METHODS A prospective cohort of 270 patients with […]
Investigation of non-invasive tests for fibrosis diagnosis and prognostication of events in metabolic dysfunction-associated steatotic liver disease: A prospective study cohort.
September 1, 2026
Ann Hepatol